Abstract:Abstract Acute kidney injury (AKI) is a public health problem with no specific therapies in the clinic, and the underlying pathogenesis of AKI remains obscure. Bombesin receptor-activated protein(BRAP, C6ORF89 protein) was initially discovered as a ligand for a previously orphan G protein-coupled receptor bombesin-like receptor-3. At present, accepted biological effects of BRAP include cell cycle progression, wound repair, and the activation of histone deacetylases. However, its role in kidney disease is unknown. In this study, we have investigated the role of BRAP and underlying mechanisms involved in cisplatin-induced AKI. BRAP was down-regulated in mice and human kidneys with AKI. Global Bc004004(homologous of C6ORF89 in mice) deletion alleviated tubular cell apoptosis and necroptosis in cisplatin-induced AKI mice, whereas local overexpression of BRAP in kidneys aggravated them. The pan-caspase inhibitor Z-VAD pretreatments attenuated cisplatin-induced blood creatinine increase and kidney injury in wild-type mice, but not in BRAP-/- mice. The activation of MLKL was magnified by Z-VAD in cisplatin-treated mice, especially in BRAP-/- mice. The cytoprotective effect of Z-VAD was more substantial than Necrostatin-1(Nec-1, an inhibitor of necroptosis) in CP-treated human kidney proximal tubular epithelial (HK2) cells. Furthermore, Nec-1pretreatment reduced the CP-induced cell death in BRAP overexpression HK2 cells but did not work in cells with normal BRAP levels. We determined that cisplatin treatment activated NF-κB subunit P65, and inhibition of P65 increased the mRNA levels of BRAP in HK2cells. ChIP assay and Dual-luciferase reporter gene assay verified P65 binding to the C6ORF89 promoter and reduced its mRNA expression upon cisplatin treatment. Next, we found that SIRT2 was downregulated in cisplatin-induced AKI, and BRAP levels directly impacted the protein levels of SIRT2. Our findings further confirmed that BRAP regulates the SIRT2 protein levels by affecting SIRT2’s interactions with E3 ubiquitin ligase HRD1 and subsequent proteasomal degradation. Collectively, our results demonstrated that BRAP played an important role in tubular cell apoptosis and necroptosis during cisplatin-induced AKI. Safe and efficient BRAP inhibitors might be effective therapeutic options for AKI.

Suppression of BMP-7 by histone deacetylase 2 promoted apoptosis of renal tubular epithelial cells in acute kidney injury

Protective effect of schisandrin B against HK-2 apoptosis induced by Cisplatin

Pyrocatechol Alleviates Cisplatin-Induced Acute Kidney Injury by Inhibiting ROS Production

A potential adjuvant chemotherapeutics, 18β-glycyrrhetinic acid, inhibits renal tubular epithelial cells apoptosis via enhancing BMP-7 epigenetically through targeting HDAC2

Exosomal‑miR‑1184 Derived from Mesenchymal Stem Cells Alleviates Cisplatin‑associated Acute Kidney Injury.

Protective Effect Of Metalloporphyrins Against Cisplatin-Induced Kidney Injury In Mice

Pharmacological Inhibition of NADPH Oxidase Protects Against Cisplatin Induced Nephrotoxicity in Mice by Two Step Mechanism

Inhibition of HDAC8 mitigates AKI by reducing DNA damage and promoting homologous recombination repair

Blockade of histone deacetylase 6 protects against cisplatin-induced acute kidney injury.

Histone deacetylases: potential therapeutic targets in cisplatin-induced acute kidney injury

Bombesin receptor-activated protein exacerbates cisplatin-induced AKI by regulating the degradation of SIRT2

Novel PHD2/HDACs hybrid inhibitors protect against cisplatin-induced acute kidney injury

SET8 inhibition preserves PTEN to attenuate kidney cell apoptosis in cisplatin nephrotoxicity

Trichostatin A Promotes Cytotoxicity of Cisplatin, as Evidenced by Enhanced Apoptosis/Cell Death Markers

P2X7 receptor deficiency attenuates cisplatin-induced kidney injury via inhibiting NLRP3 inflammasome activation

Pre-activation of hypoxia-inducible factor 1-α using prolyl hydroxylase domain inhibitors reduces cisplatin-induced nephrotoxicity

Paracrine Activation of the Wnt/β-Catenin Pathway by Bone Marrow Stem Cell Attenuates Cisplatin-Induced Kidney Injury

Autophagy Delays Apoptosis in Renal Tubular Epithelial Cells in Cisplatin Cytotoxicity

Tubular aryl hydratocarbon receptor upregulates EZH2 to promote cellular senescence in cisplatin-induced acute kidney injury

Cisplatin-Mediated Upregulation of APE2 Binding to MYH9 Provokes Mitochondrial Fragmentation and Acute Kidney Injury

DNA Demethylase Tet2 Suppresses Cisplatin-Induced Acute Kidney Injury.